article thumbnail

NHC Submits Comments on CMS’ Proposed Rule on Marketplace Integrity and Affordability

Putting Patients First Blog

While we recognize CMS intent to strengthen program integrity and reduce fraud, we are deeply concerned that several provisions in this rule will create obstacles to coverage, increase out-of-pocket costs, and disproportionately impact vulnerable populations.

article thumbnail

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

Pharmaceutical Commerce

This has driven a staggering surge in prescriptions, with some reports indicating growth of over 5,000% since 2018 in the United States. I'll explain why this "gold rush" is fraught with peril, from a risk management and insurance perspective. So, why aren't compounded GLP-1s approved?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

80 health IT & revenue cycle up-and-comers | 2025

Beckers Hospital Review

Mr. Angelone, co-founder and chief commercial officer of MacroHealth, has over 25 years of experience in the health insurance and technology industries. Mr. Angelone has also ensured compliance with key regulations like the No Surprises Act and Transparency in Coverage rules, promoting greater transparency in healthcare pricing.

article thumbnail

How the US’s pending PIE Act will improve patient access to medication

pharmaphorum

Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDA approval process. .

article thumbnail

Is India capable of ensuring equitable access to biopharmaceuticals?

Express Pharma

To help financially weak citizens gain access to affordable healthcare, the Pradhan Mantri Jan Arogya Yojana (PMJAY) was launched in 2018, providing about 500 million Indians with a ₹5 lakh family health insurance cover that include coverage for 1,400 medical procedures as well as critical diseases like prostate cancer.

article thumbnail

External control arms and debunking real-world data myths

pharmaphorum

The US regulator has not only taken a proactive role in exploring the current and future applications of RWD, but also published the framework for its Real-World Evidence Program in 2018, which launched through the 21st Century Cures Act. This can require new processes, technologies and an organisation mind shift.”.